Stevens-Johnson syndrome and toxic epidermal necrolysis in a teaching hospital in Lomé, Togo: Retrospective study of 89 cases;Syndrome de Stevens-Johnson et nécrolyse épidermique toxique en milieu hospitalier à Lomé (Togo): Étude rétrospective de 89 cas

Medecine Tropicale

Volumn 70, Issue 3, 2010, Pages 255-258

  Saka, B ^a   Kombate K ^a   Toure, M A ^a   Akakpo, S ^a   Walla, T K ^a   Pitche P ^a  

^a UNIVERSITÉ DE LOMÉ   (Togo)

Author keywords

HIV; Stevens Johnson syndrome; Togo; Toxic epidermal necrolysis

Indexed keywords

ANTICONVULSIVE AGENT; NEVIRAPINE; NONSTEROID ANTIINFLAMMATORY AGENT; SULFONAMIDE; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIINFECTIVE AGENT;

ADULT; ARTICLE; BLINDNESS; DRY EYE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTROPHIC SCAR; MAJOR CLINICAL STUDY; MALE; RETROSPECTIVE STUDY; SEROLOGY; SEX RATIO; STEVENS JOHNSON SYNDROME; TEACHING HOSPITAL; TOXIC EPIDERMAL NECROLYSIS; VAGINA DISEASE; DRUG COMBINATION; MIDDLE AGED; MORTALITY; RISK FACTOR; TOGO; TREATMENT OUTCOME;

ADULT; ANTI-HIV AGENTS; ANTI-INFECTIVE AGENTS; DRUG THERAPY, COMBINATION; EPIDERMAL NECROLYSIS, TOXIC; FEMALE; HIV INFECTIONS; HOSPITALS, TEACHING; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; RETROSPECTIVE STUDIES; RISK FACTORS; STEVENS-JOHNSON SYNDROME; SULFONAMIDES; TOGO; TREATMENT OUTCOME;

EID: 77957004631     PISSN: 0025682X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Roujeau JC, Stern RS. Severe adverse cutaneous reactions to drugs. N Engl J Med 1994;331:1272-85.
2. Rzany B, Mockenhaupt M, Baur S, Schroder W, Stocker U, Mueller J, et al. Epidemiology of erythema exsudativum multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis in Germany (1990-1992): structure and results of a population-based registry. J Clin Epidemiol 1996;49; 769-73.
3. Roujeau JC, Kelly JP, Naldi L, Rzany B, Stem RS, Anderson T, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. N Engl J Med 1995;333:1600-7.
4. Gimnig JE, MacArthur JR. M'bang'ombe M, Kramer MH, Chizani N, Stem RS, et al. Severe cutaneous reactions to sulfadoxine-pyrimeihamine and trimethoprimsulfamethoxazole in Blantyre District, Malawi. Am J Trop Med Hyg 2006;74:738-43.
5. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. AIDS 2001;15:1843-8.
6. Rotunda A, Hirsch RJ, Scheinfeld N, Weinberg JM. Severe cutaneous reactions associated with the use of human immunodeficiency virus medications. Acta Derm Venereal 2001;83:1-9.
7. Pitché P, Padonou CS, Kombaté K, Mouzou T, Tchangaï-Walla K. Syndrome de Stevens-Johnson et nécrolyse épidermique toxique à Lomé (Togo): profil évolutif et étiologique de 40 cas. Ann Dermatol Venereal 2005;132:531-4.
8. Marne Thierno D, On S, Thiemo Ndiaye S, Ndiaye B. Syndrome de Lyell au Sénégal: responsabilité de la thiacétazone. Ann Dermatol Venereol 2001;128:1305-7.
9. Bastuji-Garin S, Rzany B, Stem RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome and erythema multiforme. Arch Dermatol 1993;129:92-6.
10. Begaud B, Evreux JC, Jouglard J, Lagier G. Imputabilité des effets inattendus ou toxiques des médicaments: actualisation de la méthode utilisée en France. Tlierapie 1985;40:111-8.
11. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes-Bavinck JN, et al. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-Study. J Invest Dermatol 2008;128:35-44.
12. Ministère de la santé du Togo: Rapport du Programme National de Lutte contre le SIDA (PNLS-Togo). Juillet 2008, 88 pages.
13. Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy 2007;62:527-31.
14. Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol 2009;145:157-62.
15. Schneck J, Fagot JP, Sekula P, Sassolas B, Roujeau JC, Mockenphaupt M. Effects of treatments on the mortality of Stevens-Johnson syndrome and toxic epidermal necrolysis: A retrospective study on patients included in the prospective EuroSCAR Study. J Am Acad Dermatol 2008;58:33-40.
16. Yamane Y, Aihara M, Ikezawa Z. Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in Japan from 2000 to 2006. Allergol Int 2007;56:419-25.
17. Roujeau JC. Syndrome de Lyell et de Stevens-Johnson. Rev Prat 2007;57:1165-70.
18. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schroder W, Roujeau JC. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. Arch Dermatol 2002;138:1019-24.
19. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes-Bavinck JN, Sidoroff A, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008;58:25-32.
20. Mouhari-Touré A, Saka B, Kombaté K, Tchangaï-Walla K, Pitché P. Tolérance clinique de la combinaison fixe générique stavudine/lamivudine/névirapine (Triomune*). Etude de 297 cas au Togo. Bull Soc Pathol Exot 2008;101:404-6.
21. Bott L, Santos C, Thumerelle C, Mars A, Deschildre A, Catteau B. Syndrome de Stevens-Johnson sévère chez l'enfant: à propos de 4 observations. Arch Pediair 2007;14:1435-8.